- Home
- LRMR vs VSTM Comparison
LRMR vs VSTM Comparison
Compare LRMR & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LRMR | VSTM |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.8M | 470.7M |
| IPO Year | 2014 | 2011 |
Fundamental Metrics
Financial Performance| Metric | LRMR | VSTM |
|---|---|---|
| Price | $4.33 | $5.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $16.50 | $16.50 |
| AVG Volume (30 Days) | 1.3M | ★ 2.0M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | N/A | $282.64 |
| Revenue Next Year | $1,816.14 | $72.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $1.73 | $4.01 |
| 52 Week High | $6.42 | $11.25 |
Technical Indicators
Market Signals| Indicator | LRMR | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 39.27 | 41.55 |
| Support Level | $4.21 | $4.80 |
| Resistance Level | $4.45 | $6.79 |
| Average True Range (ATR) | 0.22 | 0.42 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 14.21 | 10.87 |
Price Performance
Historical ComparisonAbout LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.